The agreement grants worldwide rights to the partner for the development and commercialisation of a recombinant human hyaluronidase developed using Alteogen's Hybrozyme platform
Profit after tax (PAT) rose 36.2% to Rs. 292.5 crore, while PAT margin expanded 110 basis points to 11.3%
The company reported EBITDA of Rs 902 crore, while continued balance sheet optimisation helped reduce interest costs by 23% year-on-year, supporting overall profitability
The vaccine has undergone extensive laboratory evaluation, including tests for sterility, purity, safety, genetic stability, immunogenicity, protective efficacy and virulence reversion
FDA-approved aflibercept biosimilar strengthens Biocon's ophthalmology portfolio and expands patient access to affordable vision care
Published research suggests six-in-one vaccine may reduce injections, ease health worker workload, lower cold-chain needs, and become cost-effective with affordable pricing
The collaboration will initially focus on client programs involving complex biologics, including bispecific and multispecific antibodies, fusion proteins and high-concentration formulations
LEQEMBI is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer's disease
Company’s oncology business also recorded significant growth, led by Jemperli (dostarlimab) and Zejula (niraparib), both launched in August last year
Consolidated revenue from operations grows to Rs. 257.5 crore, driven by strong business momentum and improved profitability
The platform is designed to support efficient protein maturation and proteolytic processing while delivering enhanced biologic activity and higher yields for complex coagulation factors
Kiran Mazumdar-Shaw assumes Executive Chairperson role as company navigates biologics headwinds
During the two-month residential program, scholars will work on research spanning artificial intelligence, machine learning, drug discovery, healthcare, cheminformatics, genomics, and related fields
The technology transfer will transition manufacturing processes, analytical methods, and technical expertise from the current clinical-stage facility to a commercial-scale, cGMP-ready manufacturing site
Acquisition adds first-in-class anti-CD122 antibody FB102 to argenx's portfolio as Forte prepares Phase II data
Evidence-based online course aims to improve health literacy and raise awareness about adult immunisation in India
Biocon Foundation, in association with IISc and TANUH, convened national experts at the 7th Oral Cancer Task Force Annual Conference to advance India’s oral cancer elimination roadmap
US-based Mylan Inc. divests entire holding of 9.19 million shares in Biocon
The launch comes as AI models rapidly expand the ability to generate hundreds or thousands of antibody candidates in a single design cycle
CDSCO approval authorises the sale and distribution of RELOPDUO, a fixed-dose combination of nivolumab and relatlimab, for adult and paediatric patients aged 12 years and above with unresectable or metastatic melanoma
Subscribe To Our Newsletter & Stay Updated
